Merck's Q4 and full-year 2011 earnings call reveals a balanced performance with growth in key products and successful cost management strategies. However, the upcoming SINGULAIR patent expiry and European market challenges create short-term uncertainties. The company's focus on emerging markets and strategic R&D investments for long-term growth are positive signals. Overall, these mixed short-term and promising long-term prospects lead to a neutral impact on the stock in the next 1â€“2 weeks.  0